Stay current on pertinent research coming out of eye care conferences across the industry. Our abbreviated video series features Key Opinion Leaders (KOLs) as they walk through poster presentations with relevant findings.
Aflibercept 8mg in Neovascular AMD and DMO: Insights from PULSAR and PHOTON Trials
Faricimab in the Real World
Impact of Disease Activity Criteria on Dosing Interval Assignment in Clinical Trials in nAMD
Individualized Faricimab Dosing up to Every 16 Weeks Maintains Robust Anatomic and Vision Outcomes Through 2 Years in nAMD
Durable Vision Gains and Greater Fluid Control With Extended Faricimab Dosing vs Aflibercept in Patients With DME
The TRUCKEE Study: Real-World Efficacy and Safety of Faricimab in Neovascular AMD
Rapid Readout: Angiopoietin-2 (Ang2) Inhibition in the Treatment of Diabetic Macular Edema and Exudative AMD.